Key result
Fibrinolytic therapy was successful in 78.9% of patients with prosthetic heart valve thrombosis, with mortality increasing from 0% in functional class II to 23.6% in functional class IV.
Why the study?
Prosthetic heart valve thrombosis is a potentially fatal complication of mechanical valve replacement, prompting evaluation of patient clinical profiles and presentation NYHA functional class as a predictor of fibrinolytic therapy outcomes.
Does NYHA functional class on presentation predict the outcome of fibrinolytic therapy in patients with prosthetic heart valve thrombosis?
Observational (n=133)
No
Does NYHA functional class on presentation predict the outcome of fibrinolytic therapy in patients with prosthetic heart valve thrombosis?
Fibrinolytic therapy is an effective first-line treatment for prosthetic heart valve thrombosis, and higher NYHA functional class on presentation is associated with increased mortality.
Answers are grounded in this paper and cite their sources.
May guide NYHA-based risk stratification for fibrinolysis in prosthetic valve thrombosis; leaves open need for randomized confirmation.
Background: Prosthetic heart valve thrombosis (PHVT) is a potentially fatal complication of heart valve replacement with mechanical prostheses mainly due to thrombosis.Aim: The study aimed to evaluate the clinical profile of the patients presenting with PHVT undergoing fibrinolytic therapy and analyzing patients with respect to New York Heart Association (NYHA) functional class on presentation and its association with outcome of fibrinolytic therapy.Settings & design: This was prospective, observational study conducted from June, 2016 to April, 2017. Total 133 patients with prosthetic heart valve thrombosis were included. Materials and methods: Routine blood investigations included complete hemogram, liver and renal function tests. Prothrombin time with INR was done on admission. The diagnosis of PHVT was assessed by fluoroscopy and/or echocardiography (transthoracic/transesophageal). Follow-up at 6 months was scheduled for all patients.Statistical analysis: Parametric values between two groups were performed using the independent sample t-test or chi-square test, as appropriate. Univariate and multivariate logistic regression was used to find out factors associated with outcome.Results: All patients received fibrinolytic therapy in which 108 (81.2%) were treated with streptokinase and 25 (18.8%) were treated with urokinase. On presentation, 48.9% patients were in NYHA class III, 41.4% in NYHA class IV and 9.77% in NYHA class II. Fibrinolytic therapy was successful in 105 patients (78.9%) and it failed in 28 patients (21.1%). Mortality in NYHA class II was 0%, NYHA class III was 4.6% and in NYHA class IV was 23.6%. During 6 months follow up prosthetic heart valve thrombosis recurred in 12 (11.43%) patients.Conclusion: From our single centre experience, fibrinolytic therapy is fairly effective first line therapy for prosthetic heart valve thrombosis and NYHA functional class on presentation can predict the outcome of fibrinolytic therapy.
No takes yet. Share an insight, caveat, or question.
Bhatia et al. (2020) conducted an observational in Prosthetic heart valve thrombosis (n=133). Fibrinolytic therapy was evaluated on Success of fibrinolytic therapy. Fibrinolytic therapy was successful in 78.9% of patients with prosthetic heart valve thrombosis, with mortality increasing from 0% in functional class II to 23.6% in functional class IV.
Synapse has enriched 10 related papers. Consider them for comparative context: